Trending News

NuCana (NASDAQ: NCNA) announced plans to implement a significant change in its American Depositary Shares (ADS) ratio. The company will modify the ratio from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares, effective around August 8, 2025.

This change effectively functions as a 1-for-200 reverse ADS split. The move aims to enhance ADS liquidity and help NuCana regain compliance with Nasdaq's minimum bid price requirement. While holders' proportional equity interest remains unchanged, the ADS trading price is expected to increase proportionally, though this is not guaranteed.

Amylyx Pharmaceuticals (NASDAQ: AMLX) presented new exploratory analyses from Phase 2 and Phase 2b trials of avexitide, a first-in-class GLP-1 receptor antagonist, at ENDO 2025. The drug, which has FDA Breakthrough Therapy designation, showed promising results for post-bariatric hypoglycemia (PBH) treatment.

Key findings include a 64% reduction in Level 2 and Level 3 hypoglycemic events with avexitide 90 mg once daily, with over half of participants experiencing no events during treatment. Pharmacokinetic data confirmed sustained therapeutic exposure for 24 hours. The pivotal Phase 3 LUCIDITY trial is currently ongoing, with recruitment completion expected in 2025 and topline data in first half of 2026.

Rhythm Pharmaceuticals (NASDAQ:RYTM) presented significant clinical data for two MC4R agonists - setmelanotide and bivamelagon - in treating acquired hypothalamic obesity at ENDO 2025. The Phase 2 SIGNAL trial for bivamelagon showed significant BMI reductions of up to 9.3% in the highest dose cohort. The Phase 3 TRANSCEND trial for setmelanotide demonstrated a remarkable 19.8% placebo-adjusted BMI reduction across 120 patients.

Notably, setmelanotide showed consistent efficacy across age groups and genders, with significant results even in patients using GLP-1s. Patients with prior and concomitant GLP-1 use achieved a 25.1% BMI reduction compared to 2.0% in the placebo group. In patients under 18, the treatment led to a 26.2% reduction in the 95th percentile BMI at week 52.

Ultragenyx Pharmaceutical (NASDAQ: RARE) has received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for UX111, a gene therapy treatment for Sanfilippo syndrome type A. The FDA cited specific chemistry, manufacturing and controls (CMC) related observations that require resolution.

While the FDA acknowledged the robustness of clinical data and supportive biomarker evidence, this delay pushes the potential approval timeline to 2026. The company believes the CMC observations are addressable and primarily relate to facilities and processes, not product quality. After resolving these issues, Ultragenyx plans to resubmit the BLA, which will be followed by an estimated 6-month review period.

Colombier Acquisition Corp. II (NYSE:CLBR) announced minimal redemption requests for its upcoming business combination with GrabAGun.com, an online firearms and ammunition retailer. The SPAC expects to deliver over $179.1 million in gross proceeds to GrabAGun Digital Holdings, representing nearly 100% of the trust account funds.

The extraordinary general meeting is scheduled for July 15, 2025, where shareholders will vote on the business combination. Upon completion, the combined company will trade on NYSE under the symbols "PEW" and "PEWW". If all redemption requests are satisfied, 16,995,268 public shares of Colombier II would remain outstanding.

Verastem Oncology (Nasdaq: VSTM) announced the publication of primary results from its Phase 2 RAMP 201 trial in the Journal of Clinical Oncology, evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

The study demonstrated significant efficacy with an overall response rate of 31% across all patients, with particularly strong results in KRAS-mutant patients (44% ORR) compared to KRAS wild-type (17% ORR). The median progression-free survival was 12.9 months overall, extending to 22.0 months in KRAS-mutant patients. Notably, 82% of patients showed tumor reduction regardless of KRAS mutation status.

The combination therapy showed a favorable safety profile with only 10% discontinuation rate due to adverse events. The most common side effects included nausea (67%), increased creatine phosphokinase levels (60%), and diarrhea (58.3%).

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced new long-term data for PALSONIFY™ (paltusotine), their investigational once-daily oral treatment for acromegaly, to be presented at ENDO 2025. The data comes from open-label extensions of two Phase 3 trials: PATHFNDR-1 and PATHFNDR-2.

Key findings through Week 96 show that PALSONIFY maintained stable IGF-1 levels in patients who switched from injectable treatments, with mean IGF-1 levels of 0.81 times the upper limit of normal. In PATHFNDR-2, patients showed sustained IGF-1 reductions, with a mean change of -0.81 × ULN at Week 84. The drug demonstrated durable biochemical control, reduced symptom burden, and was generally well-tolerated across both studies.

Amazon (NASDAQ:AMZN) announced record-breaking results for its Prime Day 2025, which was extended to a four-day shopping event. The company reported that Prime members saved billions across more than 35 product categories, marking the highest savings in any Prime Day event to date.

Key highlights include millions of Alexa-enabled devices sold, with Ring Battery Doorbell and Fire TV Stick HD emerging as bestsellers. The event featured significant deals on popular brands like Dyson, medicube, and Philips Sonicare. Independent sellers, primarily small and medium-sized businesses, achieved record sales and item volumes.

The shopping experience was enhanced by AI-powered features including Alexa+ and Rufus, complementing Prime's fast, free delivery services. Members also enjoyed exclusive grocery deals, including 50% off ice cream at Whole Foods Market and $30 off purchases of $150+ at Amazon Fresh.

Diginex Limited (NASDAQ: DGNX), a Sustainability RegTech solutions provider, reported strong financial results for FY2025. The company achieved a 57% revenue increase to $2.0 million, primarily driven by software subscriptions and license fees. Despite recording a net loss of $5.2 million, Diginex transformed its balance sheet from net liabilities of $23.0 million to net assets of $4.6 million following its January 2025 IPO.

Post fiscal year, Diginex announced two strategic acquisition plans: Resulticks Group for approximately $2 billion and Matter DK ApS for $13 million, both in share-based transactions. The company also signed an MOU to pursue a dual listing on the Abu Dhabi Securities Exchange, including a planned capital raise of up to $250 million focused on GCC institutional investors.